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OBJECTIVEdGroup medical clinics (GMC) combine medication management and self-
management training, and may improve diabetes outcomes. It remains unclear which patients
benefit most from GMC. This secondary analysis examined the impact of baseline insulin reg-
imen on GMC response.
RESEARCHDESIGNANDMETHODSdWe analyzed a trial of 239 veterans with type 2
diabetes randomized to GMC or usual care (UC). We categorized baseline insulin regimen as the
following: no insulin; basal insulin only; or complex insulin (basal–prandial or mixed regimens).
Using linear mixed models adjusted for clustering within GMC, we evaluated the differential
impact of GMC relative to UC on hemoglobin A1c (HbA1c) and self-efficacy among patients on
different baseline insulin regimens.
RESULTSdFrom linear mixed models, the effect of GMC on HbA1c differed by baseline in-
sulin regimen versus UC (P = 0.05); there was no differential effect on self-efficacy (P = 0.29).
Among those using complex insulin regimens at baseline, GMC reduced HbA1c by study end
compared with UC (21.0%; 95% CI 21.8 to 20.2; P = 0.01). We found no such HbA1c
difference between GMC and UC patients using no insulin (P = 0.65) or basal insulin only
(P = 0.71). There were no clinically significant differences in hypoglycemia by baseline insulin
regimen and intervention group.
CONCLUSIONSdWe found that compared with UC, GMC lowered HbA1c specifically
among patients using complex insulin regimens at study baseline, which may relate to this
group’s demanding medication and self-management requirements. Implementing GMC among
patients using complex insulin regimens may maximize this care delivery strategy’s potential.
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D iabetes is increasingly prevalent (1),and the costs of poor glycemic con-trol are increasing (2,3). Because
improving hemoglobin A1c (HbA1c) leads
to reduction in diabetes complications
(4,5), addressing poor glycemic control
is vital. Good self-care is a key predictor
for attaining improved HbA1c in patients
with suboptimal glycemic control (6), so
interventions that target deficiencies in
diabetes self-management hold substan-
tial promise.
Group medical clinics (GMC) offer an
opportunity to provide patients with di-
abetes with both individualized medical
management and self-management edu-
cation in a manner that could potentially
improve access and decrease costs com-
pared with usual care (UC) (7). Random-
ized controlled trials (RCT) of GMC have
reported conflicting results among
patients with diabetes, with some studies
showing a greater improvement in HbA1c
with GMC relative to UC, and with some
studies showing no difference (8–19). It
remains unclear whether certain sub-
groups of patients may derive greater ben-
efit from diabetes GMC than others; for
example, a recent systematic review dem-
onstrated that baseline HbA1c does not
appear to be a significant predictor of
GMC response (20). Selection of high-
yield patient subgroups will be essential
to efficiently implementing GMC.
Relative to patients using oral diabe-
tes agents and/or basal insulin, patients
using complex insulin regimens (defined
for this study as multiple daily injections
of either basal and prandial insulin or
mixed basal–prandial insulin prepara-
tions) require careful insulin titration,
which some primary care providers lack
comfort in overseeing (21–25). Further,
these patients have demanding self-
management requirements, including
regular blood glucose monitoring, fre-
quent insulin administration, and nutri-
tional restrictions (26). Consequently,
self-management adherence is more chal-
lenging for patients using complex insulin
regimens than for patients using simpler
diabetes medication regimens (27). Be-
cause diabetes GMC appear to exert positive
effects by providing both tailored medica-
tion management and self-management
training (20), it is possible that GMC may
have the greatest potential for impact among
patients using complex insulin regimens.
Using data from a published random-
ized trial (16), we sought to evaluate the
effect of aGMC intervention amongpatients
with poorly controlled type 2 diabetes who
at study baseline were prescribed no insulin
(oral diabetes medications only), basal insu-
lin only (in addition to any oral medica-
tions), or complex insulin regimens (in
addition to any oral medications). Because
of their higher medication complexity and
more demanding self-management, we hy-
pothesized that patients using complex in-
sulin regimens at study baseline would
derive greater benefit from GMC relative
to UC than would patients using simpler
diabetes treatment regimens.
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RESEARCH DESIGN AND
METHODS
Group visits, population, and study
design
The RCT (NCT00286741, ClinicalTrials.
gov) on which this post hoc exploratory
analysis is based evaluated the impact of a
GMC intervention compared with UC
among 239 patients at two Veterans
Affairs Medical Centers (VAMC). Patients
were eligible for the RCT if they were
enrolled in primary care at either center,
had poorly controlled type 2 diabetes
(HbA1c $7.5%) and hypertension (sys-
tolic blood pressure [BP] $140 mmHg
or diastolic BP $90 mmHg), and used
medication for diabetes and hyperten-
sion. Patients were excluded if they re-
ported dual primary care outside of their
VAMC, were enrolled in an endocrinol-
ogy clinic in the past 6 months, were hos-
pitalized for a psychotic illness in the past
3 years, were cognitively impaired, or
had a reduced life expectancy from severe
chronic illness. Both VAMC facilities’
Institutional Review Boards approved
the protocol.
Patients were enrolled between June
2006 and September 2007 and were
randomized to either the GMC or the
UC group in a 5:4 ratio (to account
for clustering of patients in the GMC
group). Randomization was stratified by
site, baseline HbA1c control ($9.0 vs.
,9.0%), and baseline systolic BP ($150
mmHg vs. ,150 mmHg). An unblinded
individual with no responsibility for out-
come ascertainment revealed study group
allocation to patients. Trial duration was
;12 months, with assessments at study
baseline, midpoint (median 6.8 months),
and end (median 12.8months). This trial’s
primary analysis showed that GMC
improved BP but not HbA1c relative to
UC (16).
GMC intervention
The GMC intervention for the RCT on
which this analysis is based is described in
detail elsewhere (see Supplementary Ap-
pendix of parent trial) (16). Briefly, after
collection of baseline information (in-
cluding demographic and questionnaire
data, baseline systolic BP, and baseline
HbA1c) at the initial study visit, patients
randomly assigned to the GMC group
chose a group that met on their preferred
half-day. Groups each included 7–9 pa-
tients, met every 2 months (7 sessions of
120-min each over 12 months), and had
a consistent care team comprising a
primary care general internist, a pharma-
cist, and a nurse or certified diabetes ed-
ucator. Different groups had different care
teams, and each provider could be a
member of more than one care team.
Each GMC session was divided into
three phases. Phase 1 was devoted to
intake and data collection. On presenta-
tion, each patient completed a brief med-
ical questionnaire and had BP checked.
Amember of the care team collected blood
glucose data brought by patients. Intake
also allowed time for informal conversa-
tion among group members. Phase 2 was
devoted to an interactive group educa-
tional session provided by the assigned
educator. Group members selected the
schedule of educational topics for sub-
sequent visits at the initial group visit.
Concurrently, the clinical pharmacist or
internist or both reviewed medical re-
cords, BP, and home blood glucose read-
ings for each patient and developed a
medication and lifestyle management
plan directed toward improving HbA1c
and BP. In phase 3, the clinical pharmacist
or internist or both met individually with
each patient to gather additional patient-
specific information about medication
use behavior, possible adverse drug
events, or other changes in health care
status that could alter the treatment
plan. The provider and patient then
negotiated a final plan for improved dis-
ease control, which was entered into the
electronic medical record, and patients
received an updated list of their medica-
tions with instructions for any medication
or lifestyle changes. Telephone contact
with patients between GMC sessions
was limited to communicating the results
of laboratory tests obtained during the
GMC and any management changes
based on those results.
Usual primary care
Patients in the UC group received their
usual primary care but no active interven-
tion. Intervention patients continued to
receive their usual primary care in addition
to the GMC sessions. Primary care provid-
ers were informed of any medication
changes via the electronic medical record.
Definition of baseline insulin
categories
We used medication data collected at
baseline to create a categorical variable
reflecting baseline insulin regimen. Patients
were categorized as using the following: no
insulin (oral diabetes medications only,
including biguanides, sulfonylureas, or
thiazolidinediones); basal (long-acting) in-
sulin in addition to any oralmedications; or
complex insulin regimens in addition to
any oral medications. Complex insulin
regimens included basal–prandial insulin
regimens (injection of basal insulin one to
two times daily and short-acting or rapid-
acting insulin with each meal) and mixed
insulin regimens (including premixed
preparations of basal and prandial insulin
and regimens requiring the concurrent in-
jection of basal and prandial insulin twice
daily). Of note, no patients used noninsulin
injectable medications, such as glucagon-
like peptide-1 agonists, at study baseline.
One patient used twice-daily U500 regular
insulin at baseline along with aspart insulin
three times daily with meals. Although
U500 regular insulin is not a classic basal
insulin, this patient was classified as using a
complex insulin regimen based on the
manner in which the two insulin types
had been prescribed.
Outcomes
The primary outcome for this analysis was
change in HbA1c from study baseline to
study end (HbA1c measured at baseline,
midpoint, and end). Clinical laboratories
in each facility measured HbA1c by using
standard high-pressure liquid chroma-
tography methods. A secondary outcome
for this analysis was self-efficacy mea-
sured by the Perceived Competence Scale
(PCS) at study baseline, midpoint, and
end. The PCS assesses the general ability
of participants to make or maintain a
change toward a healthy behavior, partic-
ipate in a health care program, or
complete a treatment regimen. Research
has shown that improved perceived com-
petence increases the likelihood of mak-
ing or maintaining change that leads to
better health outcomes; the scale has
been validated in patients with diabetes
and has strong internal consistency (28–
30). The PCS consists of four items in
which the responses are summed and
scores can range from 4 to 20 points.
We also ascertained GMC attendance
rates and rates of hypoglycemia (defined
as a recorded blood glucose level ,3.33
mmol/L [,60 mg/dL] or a self-report of
symptomatic hypoglycemia and serious
hypoglycemia as any such episode that
required medical assistance).
Statistical analysis
All analyses were performed using
SAS software (SAS Institute, Cary, NC).
Descriptive statistics were used to char-
acterize the sample, attendance at GMC
care.diabetesjournals.org DIABETES CARE, VOLUME 36, JULY 2013 1955
Crowley and Associates
sessions, and hypoglycemic events by
baseline insulin regimen. To assess dif-
ferences in demographic and clinical char-
acteristics between baseline insulin
categories, one-way ANOVA was used
for continuous variables and the Pearson
exact x2 test was used for categorical var-
iables. We used t tests to assess differences
in the mean number of hypoglycemic
events during the study between treat-
ment groups by insulin regimen.
For HbA1c and self-efficacy, we fit lin-
ear mixed models. Because these data are
from an RCT, models were fit with a com-
mon baseline across treatment groups by
insulin regimen (31–33). The primary pre-
dictors included baseline insulin regimen
indicator variables, follow-up indicator var-
iables, intervention group by follow-up in-
dicator variables, baseline insulin regimen
by follow-up indicator variables, and then
the three-way baseline insulin regimen by
intervention group by follow-up indicator
variables. Contrasts of model parameters
were set to estimate the differential effects
of GMC compared with UC on outcomes
by baseline insulin regimen between study
baseline and follow-up.
A benefit of using a mixed-model
framework for longitudinal analysis is
that unbalanced or incomplete data are
allowed and all patients with partial data
for the outcome variables are included in
the analyses (34). For the repeated mea-
sures over time, we used an unstructured
covariance; we also fit a random GMC
effect within the intervention arm to
account for the clustering of subjects
within the GMC. Models also included
our stratification variables of site, baseline
BP (systolic BP $150 mmHg vs. systolic
BP , 150 mmHg) and baseline HbA1c
(HbA1c $9.0 vs. ,9.0%).
RESULTS
Patient characteristics
Two-hundred thirty-nine patients were
enrolled in the study, with 133 patients
randomized to GMC and 106 patients
randomized to UC. Two-hundred fifteen
patients (90%) completed midpoint
study follow-up, and 211 patients (88%)
completed the trial; we obtained 93% of
data points. Table 1 provides patient
characteristics by baseline insulin cate-
gory. The study sample participants
were predominantly male, African Amer-
ican or white, and had poorly controlled
diabetes and hypertension. Of the 239 pa-
tients in the study, 41% (n = 98) used oral
diabetes medications only, 26% (n = 62)
used basal insulin in addition to any oral
medications, and 33% (n = 79) used com-
plex insulin regimens. The three insulin
regimen groups were similar at baseline in
terms of age, sex, race, marital status, ed-
ucation level, and baseline HbA1c, systolic
BP, and PCS.
GMC attendance by baseline insulin
category
Overall, intervention patients attended
78.4% of the GMC sessions, and atten-
dance was higher at the Richmond VAMC
(86% of sessions attended) than at the
Durham VAMC (70% of sessions attended).
Attendance did not differ markedly
between the three baseline insulin reg-
imen groups; patients using no insulin
(oral agents only) attended 79% of the
sessions, patients using basal insulin in
addition to oral agents attended 82%
of the sessions, and patients using com-
plex insulin regimens attended 74% of the
sessions.
GMC intervention effects by baseline
insulin category
From linear mixed models, we found
evidence for a differential intervention ef-
fect by baseline insulin regimen on HbA1c
over time (P = 0.05). GMC patients using
complex insulin regimens had a greater re-
duction in HbA1c compared with UC from
baseline to midpoint (21.0%; 95% CI,
21.8 to 20.3; P = 0.01) and baseline to
study end (21.0%; 21.8 to 20.2; P =
0.01) (Table 2, Fig. 1). We found no
HbA1c difference between GMC and UC
patients whose baseline regimens included
no insulin or basal insulin only from base-
line to midpoint (P = 0.90 and P = 0.30,
respectively) or from baseline to study end
(P = 0.65 and P = 0.71, respectively)
(Fig. 1). Thus, whereasGMCpatients using
complex insulin regimens at study baseline
showed significantly greater HbA1c im-
provement during the study compared
with UC, patients using simpler regimens
(no insulin or only basal insulin) had







(n = 79) P†
Age (years), mean (SD) 62.0 (10.0) 63.2 (10.2) 61.2 (9.1) 0.5
Male, % 96.9 98.4 92.4 0.2
Race, %
White 38.8 33.9 35.4 1.0
African American 57.1 61.3 59.5
Other 4.1 4.8 5.1
Marital status, %
Married 56.1 54.8 64.6 0.2
Divorced or separated 31.6 22.6 21.5
Widowed 6.1 9.7 10.1
Never married 6.1 12.9 3.8
Education, %
High school or less 38.8 43.6 39.2 0.5
Some college 37.8 43.6 43.0
College graduate or more 23.5 12.9 17.7
Financial burden, %
Can pay bills without cutting spending 69.9 75.8 57.1 0.06
Can pay bills only by cutting spending
or cannot always pay bills 30.1 24.2 42.9
Clinical data, mean (SD)
HbA1c (%) 9.0 (1.6) 9.1 (1.1) 9.3 (1.3) 0.4
Systolic BP (mmHg) 154.2 (16.0) 151.0 (11.8) 152.9 (13.6) 0.4
PCS, mean (SD) 14.0 (3.4) 14.4 (3.6) 14.1 (3.6) 0.8
*One patient in the complex insulin regimen group was missing data for education level. Five patients in the
no insulin group and two patients in the complex insulin regimen group were missing data for financial
burden. Five patients in the no insulin regimen category, three patients in the basal only regimen category,
and two patients in the complex regimen category were missing a score for the PCS. Those with missing data
were excluded from percentage calculations. †For continuous variables, a one-way ANOVAwas conducted to
test for differences in baseline characteristics between insulin treatment regimen groups. For categorical
variables, exact Pearson x2 tests were conducted to test for differences between insulin treatment regimen
groups.
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similar estimated change in HbA1c regard-
less of intervention status (Fig. 1).
Although estimated mean self-efficacy
scores did improve overall among GMC
patients compared with UC, we found no
evidence from linear mixed models of a
differential intervention effect over time by
baseline insulin regimen for self-efficacy
(P=0.29). Patients in theGMCgroupusing
either no insulin or complex insulin had
higher mean scores on self-efficacy than
UC at the end of study (2.1 points and
95% CI, 1.0–3.3 [P = 0.0004] and 2.0
points and 0.6–3.3 [P = 0.004], respec-
tively), but self-efficacy did not differ sig-
nificantly between GMC versus UC
patients in the basal insulin only group
(P = 0.7) (Table 2).
Hypoglycemia by baseline insulin
category
Among those using no insulin at baseline,
UC patients experienced a mean 6 SD of
1.1 6 0.9 hypoglycemic events during
Table 2dModel estimates by baseline insulin category, study intervention group, and follow-up time
Follow-up
Midpoint End of study
Difference in change (follow up–baseline) by diabetes
regimen for GMC vs. UC (95% CI); P value
Midpoint End of study
Outcome or regimen category* Baseline† GMC UC GMC UC GMC vs. UC GMC vs. UC
HbA1c
No insulin 9.2 8.8 8.8 8.3 8.2 0.0 (20.6 to 0.7); 0.90 0.2 (20.5 to .9); 0.6
Basal only 9.0 8.6 8.2 8.6 8.8 0.4 (20.4 to 1.3); 0.30 20.2 (21.1 to 0.7); 0.7
Complex 9.2 8.4 9.4 8.0 9.1 21.0 (21.8 to 20.3); 0.01 21.0 (21.8 to 20.2); 0.01
PCS‡
No insulin 13.9 15.8 14.5 16.6 14.5 1.3 (0.2–2.5); 0.02 2.1 (1.0–3.3); 0.0004
Basal only 14.4 15.8 15.8 15.8 15.4 0.0 (21.4 to 1.3); 1.00 0.3 (21.1 to 1.8); 0.7
Complex 14.0 15.5 14.7 15.7 13.8 0.8 (20.4 to 2.1); 0.20 2.0 (0.6–3.3); 0.004
*Twenty-five patients were missing HbA1c values at midpoint (GMC = 11; UC = 14) and 28 patients were missing HbA1c at the end of the study (GMC = 10; UC = 18).
Twenty-nine patients weremissing PCS scores at midpoint (GMC= 13; UC = 16) and 30 patients weremissing PCS scores at the end of the study (GMC= 11; UC = 19).
†Common baseline across treatment groups by insulin regimen category. ‡The potential range of the PCS measure is 4 to 20, with higher scores indicating more
confidence in managing their diabetes.
Figure 1dModel estimates and 95% CI of change in HbA1c from baseline to end of study by insulin regimen category and study intervention group.
P values are from test of difference in change of HbA1c between GMC and UC within diabetes regimen.
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the study, as opposed to 0.9 6 0.9 in the
GMC group (P = 0.86). Among those
using basal insulin only, UC patients
experienced a mean of 1.4 6 1.0 hypogly-
cemic events, as opposed to 0.960.6 in the
GMC group (P = 0.04). Among those using
complex insulin regimens, UC patients
experienced a mean of 1.4 6 1.0 hypogly-
cemic events, as opposed to 1.861.0 in the
GMC group (P = 0.96).
CONCLUSIONSdGMC show prom-
ise as a means to simultaneously address
medication management and patient self-
management deficiencies among individ-
uals with diabetes and other chronic
diseases. The randomized trial on which
the current study is based demonstrated
that GMC improved BP but not HbA1c
among veterans with poorly controlled
type 2 diabetes and hypertension. How-
ever, it has remained unclear whether cer-
tain subgroups of patients with diabetes
may derive greater HbA1c lowering from
GMC. This post hoc analysis indicates
that patients using complex insulin regi-
mens at study baseline had a significantly
greater improvement in glycemic control
with GMC as compared with UC. These
findings stand in contrast to those for pa-
tients using simpler diabetes regimens (no
insulin or basal insulin only) in which we
found no difference in the degree of
HbA1c improvement between GMC and
UC groups. Our finding that baseline in-
sulin regimen appears to be a moderator
for GMC response may have important
implications for future research and im-
plementation of GMC in clinical practice.
Two factors may explain the particu-
lar improvement in glycemic control we
noted among GMC patients using com-
plex insulin regimens at study baseline.
First, management of complex insulin
regimens requires a comfort with insulin
titration that some primary care providers
lack (21–25). Medicationmanagement by
an experienced physician or clinical phar-
macist, or both, through GMC therefore
may yield greater potential for HbA1c im-
provement than UC among patients using
complex insulin regimens. Second, com-
pared with patients using simpler diabe-
tes regimens, patients using complex
insulin regimens generally have a greater
self-management burden, including more
frequent blood glucose monitoring, more
frequent medication administration,
more stringent restrictions regarding
meal timing and content, and a greater
need for hypoglycemia monitoring
and management (26). Studies have
consistently demonstrated that diabetes
self-management training from certified
nurse educators, which GMC can pro-
vide, is more effective than UC in improv-
ing diabetes self-management (35), which
may, in turn, translate to improved HbA1c
(36,37). Because treating patients using
complex insulin regimens requires both
complicated medication management
and self-management training, it is logical
that these individuals would exhibit
superior outcomes with GMC, in which
both medication management and self-
management training are readily avail-
able, as compared with UC. GMC patients
using complex insulin regimens achieved
the observed improvements in HbA1c
without experiencing significantly in-
creased rates of hypoglycemia.
We found no significant differential
effect of the GMC intervention on PCS by
baseline insulin regimen. However, the
GMC intervention appeared to positively
impact self-efficacy among patients using
no insulin and complex insulin compared
with UC. The PCS is a validated measure
of general self-efficacy among patients
with diabetes, and it was well-suited to
assess self-efficacy pertaining to diabetes
and hypertension for the purposes of the
parent RCT. However, a detailed measure
of diabetes-related self-efficacy (38), as
well as additional measures such as
diabetes-related emotional distress (39),
would be more informative when exam-
ining the differential effect of the GMC
intervention by insulin regimen. One
might hypothesize that self-efficacy may,
in part, mediate the effect of baseline in-
sulin regimen by treatment group on
HbA1c, but a formal mediation analysis
in a longitudinal framework is beyond
the scope of this article. Future studies
should evaluate whether self-efficacy
and other psychometric variables may
mediate the impact of baseline insulin
regimen on GMC response.
Although individuals using oral di-
abetes medications only seemed to benefit
from GMC in terms of HbA1c lowering,
our findings suggested that UC was
equally effective in this regard among
these patients. Patients using basal insulin
with or without oral medications ap-
peared to show less response to GMC
and UC than did patients using oral med-
ications alone. Although the current
study cannot explain this finding, we
could hypothesize that, despite their
poor control, some in this group re-
mained using basal insulin alone at study
baseline because of resistance to further
insulin intensification, and that this resis-
tance limited the impact of GMC. The role
of patient resistance to treatment intensi-
fication in modulating the effectiveness of
GMC is another important area for further
study. Because patients using oral diabe-
tes medications with or without basal in-
sulin did not appear to derive additional
HbA1c benefit from GMC relative to UC,
baseline insulin regimen may be a key
consideration when referring patients for
diabetes GMC.
Limitations
In addition to the limitations detailed, this
analysis has other limitations. The RCT
on which this analysis is based was con-
ducted in a veteran population that was
predominantly male, which may affect
the generalizability of our results. How-
ever, because Veterans Affairs is a gener-
ally high-functioning system with respect
to diabetes outcomes (40), it is unlikely
that we are overestimating the incremen-
tal benefit of GMC over UC. Because this
is a secondary analysis, undetected cova-
riate imbalance may exist between base-
line insulin groups, so our results should
be interpreted accordingly; however, our
examination of available baseline factors
suggests that the groups were similar in
most respects. Our sample size required
us to combine patients using different
insulin regimens, such as basal–prandial
insulin regimens and mixed insulin regi-
mens, into a single “complex insulin reg-
imen” category and, even with the
categories used, our group sizes were rel-
atively small. It is possible that distinct
subpopulations within our complex insu-
lin regimen group would have distinct re-
sponses to GMC and UC, and this should
be a question for future study.
This analysis also is limited in that we
lacked data to further explore treatment
intensification among GMC and UC pa-
tients. In future studies, it will be infor-
mative to further explore patterns of
diabetes medication intensification and
to evaluate the relationship between treat-
ment intensification and intervention re-
sponse among patients randomized to
GMC and UC in different baseline insulin
regimen groups. However, because base-
line insulin regimen easily can be deter-
mined at the time of referral to a GMC
intervention, knowledge of how this fac-
tor relates to GMC response is valuable.
Despite our limitations, we demon-
strated that GMCproduced greater HbA1c
reduction than UC among patients with
poorly controlled diabetes using complex
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insulin regimens at study baseline. GMC
hold promise as a strategy for care deliv-
ery redesign among patients with diabe-
tes, and we are unaware of any previous
analysis that has identified a patient sub-
group deriving particular benefit from
GMC. Our findings suggest that to maxi-
mize HbA1c improvement relative to UC,
diabetes GMC may be best-targeted to-
ward poorly controlled patients using
complex insulin regimens.
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